



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2012	2011	% Change			2012	2011	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>CONSUMER SEGMENT <sup>(2)</sup></b>										
<b>BABY CARE</b>										
US	\$ 103	103	0.0%	0.0%	-	\$ 412	418	-1.4%	-1.4%	-
Intl	469	465	0.9%	3.5%	-2.6%	1,842	1,922	-4.2%	1.1%	-5.3%
WW	572	568	0.7%	2.8%	-2.1%	2,254	2,340	-3.7%	0.6%	-4.3%
<b>ORAL CARE</b>										
US	165	173	-4.6%	-4.6%	-	641	656	-2.3%	-2.3%	-
Intl	251	239	5.0%	6.6%	-1.6%	983	968	1.5%	6.9%	-5.4%
WW	416	412	1.0%	2.0%	-1.0%	1,624	1,624	0.0%	3.2%	-3.2%
<b>OTC/NUTRITIONALS</b>										
US	356	370	-3.8%	-3.8%	-	1,424	1,429	-0.3%	-0.3%	-
Intl	802	766	4.7%	5.7%	-1.0%	2,930	2,973	-1.4%	3.4%	-4.8%
WW	1,158	1,136	1.9%	2.6%	-0.7%	4,354	4,402	-1.1%	2.1%	-3.2%
<b>SKIN CARE</b>										
US	385	403	-4.5%	-4.5%	-	1,699	1,654	2.7%	2.7%	-
Intl	509	541	-5.9%	-3.4%	-2.5%	1,919	2,061	-6.9%	-2.0%	-4.9%
WW	894	944	-5.3%	-3.9%	-1.4%	3,618	3,715	-2.6%	0.1%	-2.7%
<b>WOMEN'S HEALTH</b>										
US	82	89	-7.9%	-7.9%	-	336	439	-23.5%	-23.5%	-
Intl	325	309	5.2%	9.4%	-4.2%	1,289	1,353	-4.7%	2.3%	-7.0%
WW	407	398	2.3%	5.5%	-3.2%	1,625	1,792	-9.3%	-4.0%	-5.3%
<b>WOUND CARE/OTHER</b>										
US	112	110	1.8%	1.8%	-	534	555	-3.8%	-3.8%	-
Intl	93	100	-7.0%	-8.0%	1.0%	438	455	-3.7%	0.6%	-4.3%
WW	205	210	-2.4%	-2.9%	0.5%	972	1,010	-3.8%	-1.8%	-2.0%
<b>TOTAL CONSUMER</b>										
US	1,203	1,248	-3.6%	-3.6%	-	5,046	5,151	-2.0%	-2.0%	-
Intl	2,449	2,420	1.2%	3.2%	-2.0%	9,401	9,732	-3.4%	1.9%	-5.3%
WW	\$ 3,652	3,668	-0.4%	0.9%	-1.3%	\$ 14,447	14,883	-2.9%	0.5%	-3.4%

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	FOURTH QUARTER					TWELVE MONTHS				
	2012	2011	% Change			2012	2011	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>PHARMACEUTICAL SEGMENT <sup>(2) (4)</sup></b>										
<b>IMMUNOLOGY</b>										
US	\$ 1,448	1,401	3.4%	3.4%	-	\$ 5,972	5,751	3.8%	3.8%	-
Intl	528	395	33.7%	35.7%	-2.0%	1,902	1,047	81.7%	86.3%	-4.6%
WW	1,976	1,796	10.0%	10.4%	-0.4%	7,874	6,798	15.8%	16.9%	-1.1%
<b>REMICADE</b>										
US	871	776	12.2%	12.2%	-	3,583	3,276	9.4%	9.4%	-
US Exports <sup>(3)</sup>	347	437	-20.6%	-20.6%	-	1,470	1,797	-18.2%	-18.2%	-
Intl	286	215	33.0%	34.4%	-1.4%	1,086	419	-	-	-4.5%
WW	1,504	1,428	5.3%	5.5%	-0.2%	6,139	5,492	11.8%	12.6%	-0.8%
<b>SIMPONI</b>										
US	72	62	16.1%	16.1%	-	292	235	24.3%	24.3%	-
Intl	109	57	91.2%	96.8%	-5.6%	315	175	80.0%	87.5%	-7.5%
WW	181	119	52.1%	54.8%	-2.7%	607	410	48.0%	51.2%	-3.2%
<b>STELARA</b>										
US	158	126	25.4%	25.4%	-	627	443	41.5%	41.5%	-
Intl	111	81	37.0%	40.1%	-3.1%	398	295	34.9%	42.4%	-7.5%
WW	269	207	30.0%	31.2%	-1.2%	1,025	738	38.9%	41.9%	-3.0%
<b>OTHER IMMUNOLOGY</b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	22	42	-47.6%	-49.4%	1.8%	103	158	-34.8%	-33.0%	-1.8%
WW	22	42	-47.6%	-49.4%	1.8%	103	158	-34.8%	-33.0%	-1.8%
<b>INFECTIOUS DISEASES</b>										
US	236	210	12.4%	12.4%	-	974	1,401	-30.5%	-30.5%	-
Intl	620	506	22.5%	26.7%	-4.2%	2,220	1,788	24.2%	32.1%	-7.9%
WW	856	716	19.6%	22.6%	-3.0%	3,194	3,189	0.2%	4.6%	-4.4%
<b>INTELENCE</b>										
US	46	45	2.2%	2.2%	-	176	163	8.0%	8.0%	-
Intl	38	38	0.0%	1.7%	-1.7%	173	151	14.6%	22.2%	-7.6%
WW	84	83	1.2%	2.0%	-0.8%	349	314	11.1%	14.8%	-3.7%
<b>LEVAQUIN/FLOXIN</b>										
US	-	(6)	*	*	-	35	579	-94.0%	-94.0%	-
Intl	10	11	-9.1%	-10.5%	1.4%	40	44	-9.1%	-5.8%	-3.3%
WW	10	5	100.0%	97.2%	2.8%	75	623	-88.0%	-87.8%	-0.2%
<b>PREZISTA</b>										
US	165	143	15.4%	15.4%	-	672	529	27.0%	27.0%	-
Intl	188	173	8.7%	12.2%	-3.5%	742	682	8.8%	16.3%	-7.5%
WW	353	316	11.7%	13.6%	-1.9%	1,414	1,211	16.8%	21.0%	-4.2%
<b>OTHER INFECTIOUS DISEASES</b>										
US	25	28	-10.7%	-10.7%	-	91	130	-30.0%	-30.0%	-
Intl	384	284	35.2%	40.5%	-5.3%	1,265	911	38.9%	47.3%	-8.4%
WW	409	312	31.1%	35.9%	-4.8%	1,356	1,041	30.3%	37.7%	-7.4%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	FOURTH QUARTER					TWELVE MONTHS					
	2012	2011	% Change			2012	2011	% Change			
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency	
<b>NEUROSCIENCE</b>											
US	601	611	-1.6%	-1.6%	-	2,611	2,617	-0.2%	-0.2%	-	
Intl	1,088	1,128	-3.5%	-1.6%	-1.9%	4,107	4,331	-5.2%	-0.8%	-4.4%	
WW	1,689	1,739	-2.9%	-1.6%	-1.3%	6,718	6,948	-3.3%	-0.5%	-2.8%	
<b>CONCERTA/METHYLPHENIDATE</b>											
US	116	155	-25.2%	-25.2%	-	609	822	-25.9%	-25.9%	-	
Intl	127	119	6.7%	8.1%	-1.4%	464	446	4.0%	8.8%	-4.8%	
WW	243	274	-11.3%	-10.7%	-0.6%	1,073	1,268	-15.4%	-13.7%	-1.7%	
<b>INVEGA</b>											
US	76	66	15.2%	15.2%	-	299	285	4.9%	4.9%	-	
Intl	71	59	20.3%	23.0%	-2.7%	251	214	17.3%	22.0%	-4.7%	
WW	147	125	17.6%	18.9%	-1.3%	550	499	10.2%	12.2%	-2.0%	
<b>INVEGA SUSTENNA/ XEPLION</b>											
US	132	99	33.3%	33.3%	-	482	319	51.1%	51.1%	-	
Intl	96	36	*	*	-2.4%	314	59	*	*	-5.7%	
WW	228	135	68.9%	69.9%	-1.0%	796	378	*	*	-2.2%	
<b>RISPERDAL CONSTA</b>											
US	103	108	-4.6%	-4.6%	-	439	443	-0.9%	-0.9%	-	
Intl	255	277	-7.9%	-5.8%	-2.1%	986	1,140	-13.5%	-8.6%	-4.9%	
WW	358	385	-7.0%	-5.5%	-1.5%	1,425	1,583	-10.0%	-6.4%	-3.6%	
<b>OTHER NEUROSCIENCE</b>											
US	174	183	-4.9%	-4.9%	-	782	748	4.5%	4.5%	-	
Intl	539	637	-15.4%	-13.7%	-1.7%	2,092	2,472	-15.4%	-11.9%	-3.5%	
WW	713	820	-13.0%	-11.7%	-1.3%	2,874	3,220	-10.7%	-8.0%	-2.7%	
<b>ONCOLOGY</b>											
US	135	95	42.1%	42.1%	-	506	331	52.9%	52.9%	-	
Intl	684	468	46.2%	49.7%	-3.5%	2,123	1,717	23.6%	29.7%	-6.1%	
WW	819	563	45.5%	48.5%	-3.0%	2,629	2,048	28.4%	33.3%	-4.9%	
<b>DOXIL/CAELYX</b>											
US	21	10	*	*	-	43	140	-69.3%	-69.3%	-	
Intl	9	29	-69.0%	-68.3%	-0.7%	40	262	-84.7%	-83.5%	-1.2%	
WW	30	39	-23.1%	-22.6%	-0.5%	83	402	-79.4%	-78.6%	-0.8%	
<b>VELCADE</b>											
US	-	-	-	-	-	-	-	-	-	-	
Intl	502	352	42.6%	47.6%	-5.0%	1,500	1,274	17.7%	24.5%	-6.8%	
WW	502	352	42.6%	47.6%	-5.0%	1,500	1,274	17.7%	24.5%	-6.8%	
<b>ZYTIGA</b>											
US	114	85	34.1%	34.1%	-	463	191	*	*	-	
Intl	150	67	*	*	-3.8%	498	110	*	*	-7.0%	
WW	264	152	73.7%	75.8%	-2.1%	961	301	*	*	-3.7%	
<b>OTHER ONCOLOGY</b>											
US	-	-	-	-	-	-	-	-	-	-	
Intl	23	20	15.0%	18.8%	-3.8%	85	71	19.7%	25.5%	-5.8%	
WW	23	20	15.0%	18.8%	-3.8%	85	71	19.7%	25.5%	-5.8%	

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	FOURTH QUARTER					TWELVE MONTHS					
	2012	2011	% Change			2012	2011	% Change			
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency	
<b>TOTAL OTHER</b>											
US	593	570	4.0%	4.0%	-	2,358	2,286	3.1%	3.1%	-	
Intl	592	710	-16.6%	-15.5%	-1.1%	2,578	3,099	-16.8%	-12.4%	-4.4%	
WW	1,185	1,280	-7.4%	-6.8%	-0.6%	4,936	5,385	-8.3%	-5.8%	-2.5%	
<b>ACIPHEX/PARIET</b>											
US	92	110	-16.4%	-16.4%	-	372	414	-10.1%	-10.1%	-	
Intl	94	144	-34.7%	-33.9%	-0.8%	463	561	-17.5%	-11.8%	-5.7%	
WW	186	254	-26.8%	-26.4%	-0.4%	835	975	-14.4%	-11.1%	-3.3%	
<b>PROCRI/EPREX</b>											
US	171	191	-10.5%	-10.5%	-	805	814	-1.1%	-1.1%	-	
Intl	155	177	-12.4%	-11.0%	-1.4%	657	809	-18.8%	-13.7%	-5.1%	
WW	326	368	-11.4%	-10.7%	-0.7%	1,462	1,623	-9.9%	-7.4%	-2.5%	
<b>OTHER</b>											
US	330	269	22.7%	22.7%	-	1,181	1,058	11.6%	11.6%	-	
Intl	343	389	-11.8%	-10.8%	-1.0%	1,458	1,729	-15.7%	-12.1%	-3.6%	
WW	673	658	2.3%	2.9%	-0.6%	2,639	2,787	-5.3%	-3.1%	-2.2%	
<b>TOTAL PHARMACEUTICAL</b>											
US	3,013	2,887	4.4%	4.4%	-	12,421	12,386	0.3%	0.3%	-	
Intl	3,512	3,207	9.5%	12.1%	-2.6%	12,930	11,982	7.9%	13.6%	-5.7%	
WW	\$ 6,525	\$ 6,094	7.1%	8.5%	-1.4%	\$ 25,351	\$ 24,368	4.0%	6.8%	-2.8%	

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	FOURTH QUARTER					TWELVE MONTHS					
	2012	2011	% Change			2012	2011	% Change			
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency	
<b>MEDICAL DEVICES AND DIAGNOSTICS <sup>(2)(4)</sup></b>											
<b>CARDIOVASCULAR CARE</b>											
US	\$ 186	191	-2.6%	-2.6%	-	\$ 752	841	-10.6%	-10.6%	-	
Intl	320	349	-8.3%	-6.6%	-1.7%	1,233	1,447	-14.8%	-11.5%	-3.3%	
WW	506	540	-6.3%	-5.2%	-1.1%	1,985	2,288	-13.2%	-11.1%	-2.1%	
<b>DIABETES CARE</b>											
US	295	330	-10.6%	-10.6%	-	1,312	1,312	0.0%	0.0%	-	
Intl	349	340	2.6%	5.2%	-2.6%	1,304	1,340	-2.7%	2.8%	-5.5%	
WW	644	670	-3.9%	-2.6%	-1.3%	2,616	2,652	-1.4%	1.4%	-2.8%	
<b>DIAGNOSTICS</b>											
US	258	280	-7.9%	-7.9%	-	1,025	1,091	-6.0%	-6.0%	-	
Intl	272	274	-0.7%	1.3%	-2.0%	1,044	1,073	-2.7%	1.0%	-3.7%	
WW	530	554	-4.3%	-3.3%	-1.0%	2,069	2,164	-4.4%	-2.6%	-1.8%	
<b>INFECTION PREVENTION/OTHER</b>											
US	86	94	-8.5%	-8.5%	-	399	377	5.8%	5.8%	-	
Intl	160	144	11.1%	13.6%	-2.5%	553	529	4.5%	8.2%	-3.7%	
WW	246	238	3.4%	4.9%	-1.5%	952	906	5.1%	7.2%	-2.1%	
<b>ORTHOPAEDICS</b>											
US	1,246	775	60.8%	60.8%	-	4,144	3,093	34.0%	34.0%	-	
Intl	1,142	678	68.4%	70.1%	-1.7%	3,655	2,716	34.6%	38.7%	-4.1%	
WW	2,388	1,453	64.3%	65.1%	-0.8%	7,799	5,809	34.3%	36.2%	-1.9%	
<b>SPECIALTY SURGERY</b>											
US	326	327	-0.3%	-0.3%	-	1,297	1,226	5.8%	5.8%	-	
Intl	329	307	7.2%	9.5%	-2.3%	1,229	1,181	4.1%	8.9%	-4.8%	
WW	655	634	3.3%	4.4%	-1.1%	2,526	2,407	4.9%	7.2%	-2.3%	
<b>SURGICAL CARE</b>											
US	618	639	-3.3%	-3.3%	-	2,415	2,465	-2.0%	-2.0%	-	
Intl	1,049	1,055	-0.6%	1.9%	-2.5%	4,068	4,172	-2.5%	2.1%	-4.6%	
WW	1,667	1,694	-1.6%	0.0%	-1.6%	6,483	6,637	-2.3%	0.6%	-2.9%	
<b>VISION CARE</b>											
US	229	214	7.0%	7.0%	-	1,019	966	5.5%	5.5%	-	
Intl	516	496	4.0%	6.1%	-2.1%	1,977	1,950	1.4%	3.7%	-2.3%	
WW	745	710	4.9%	6.4%	-1.5%	2,996	2,916	2.7%	4.3%	-1.6%	
<b>TOTAL MEDICAL DEVICES AND DIAGNOSTICS</b>											
US	3,244	2,850	13.8%	13.8%	-	12,363	11,371	8.7%	8.7%	-	
Intl	4,137	3,643	13.6%	15.8%	-2.2%	15,063	14,408	4.5%	8.6%	-4.1%	
WW	\$ 7,381	6,493	13.7%	14.9%	-1.2%	\$ 27,426	25,779	6.4%	8.7%	-2.3%	

\* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported as U.S. sales

(4) Prior year amounts have been reclassified to conform to current year product disclosure